The Lunit Group (KRX:328130.KQ), a leading provider of artificial intelligence (AI)-based cancer diagnostics and therapeutics, is partnering with NTT DATA Singapore for the introduction of Lunit INSIGHT CXR to Singapore's public healthcare system on Nov. 30, 2023.
Lunit collaborated with CARPL as part of the agreement to provide NTT DATA with Lunit INSIGHT CXR as part of the agreement. As a result, NTT DATA was able to facilitate the delivery of software to Synapxe, Singapore's national health technology agency. As part of this strategic collaboration, the solution will be seamlessly integrated into the clinical radiology workflow of Singapore General Hospital (SGH) and Changi General Hospital (CGH).. There are two award-winning public hospitals with more than 1,000 beds in Singapore that are part of SingHealth, Singapore's largest group of public healthcare institutions.
There are two award-winning public hospitals with more than 1,000 beds in Singapore that are part of SingHealth, Singapore's largest group of public healthcare institutions.
As a part of the agreement, Lunit collaborated with CARPL in order to provide NTT DATA with Lunit INSIGHT CXR as part of the agreement. It was NTT DATA who then facilitated the delivery of the software to Synapxe, Singapore's national health technology agency. A strategic collaboration between Singapore General Hospital (SGH) and Changi General Hospital (CGH) aims to seamlessly integrate the solution into the clinical radiology workflow of Singapore General Hospital (SGH) and Changi General Hospital (CGH).. It is important to note that both hospitals are award-winning public hospitals with over 1,000 beds, and they are both part of SingHealth, Singapore's largest group of public healthcare institutions.
It is important to note that both hospitals are award-winning public hospitals with over 1,000 beds, and they are both part of SingHealth, Singapore's largest group of public healthcare institutions.
The introduction of Lunit INSIGHT CXR into the chest X-ray workflow will help both hospitals to improve the efficiency and accuracy of chest X-ray screening while providing their patients with innovative medical services that are better suited to their needs.
Project AimSG: Leaping Together Towards AI Driven Healthcare Transformation: A Collaborative Leap
As part of the AimSG pilot project, Synapxe, SingHealth, Lunit, NTT DATA, and its partners (DeepTek and CARPL) have collaborated together. It is supported by the Singapore Ministry of Health (MOH) and Smart Nation Singapore. In order to optimize the diagnostic capabilities and efficiency of medical professionals, AimSG enables public health institutions to integrate AI imaging solutions, such as Lunit INSIGHT CXR, seamlessly into their existing clinical radiology workflow.
In an era when healthcare technology is becoming more complex, the AimSG platform aims to improve the ability of Singapore public healthcare institutions to validate and deploy credible AI imaging models in an environment of complex healthcare technologies.. It is possible for such an AI model to be developed within the Singapore healthcare ecosystem or it may be selected from partners within the industry. Synapxe's AimSG platform is an open, vendor-neutral platform that will serve multiple use cases such as chest X-rays, mammograms, cardiac CT, and other imaging cases in which AI is applied to clinical images," said Glenn Neo, Synapxe's Head of Innovation Capabilities Enablement.
Synapxe's AimSG platform is an open, vendor-neutral platform that will serve multiple use cases such as chest X-rays, mammograms, cardiac CT, and other imaging cases in which AI is applied to clinical images," said Glenn Neo, Synapxe's Head of Innovation Capabilities Enablement.
It has been reported that healthcare institutions that have adopted Lunit's AI solution through AimSG have had a positive response to it, and they are looking forward to its improvement of medical imaging workflows in the future.
The AimSG platform enables clinicians from public healthcare institutions to deploy AI algorithms in order to improve the quality of patient care. Dr. Charlene Liew, Director of Innovation, SingHealth Duke-NUS Radiological Sciences Academic Clinical Programme and Deputy Chief Medical Informatics Officer at Changi General Hospital, says that the '3Ps' of Preventive, Predictive, and Personalised Medicine will be enabled more effectively than ever before.
We can potentially enhance our ability to enhance the interpretation and diagnosis of chest diseases for patients by leveraging AI solutions through the AimSG platform and integrating the AI directly into the clinical workflow by harnessing AI solutions and integrating them into the clinical workflow.". Dr Chan Lai Peng, Academic Vice-chair of Clinical Service Operations of SingHealth Duke-NUS Radiological Sciences Academic Clinical Programme and Head of Diagnostic Radiology, Singapore General Hospital, stated that this approach holds the potential to facilitate and expedite patient care while minimizing the strain on the healthcare workforce.
Dr Chan Lai Peng, Academic Vice-chair of Clinical Service Operations of SingHealth Duke-NUS Radiological Sciences Academic Clinical Programme and Head of Diagnostic Radiology, Singapore General Hospital, stated that this approach holds the potential to facilitate and expedite patient care while minimizing the strain on the healthcare workforce.
Taking part in the AimSG project and working with our partners to bring Lunit INSIGHT CXR to the Singaporean public healthcare system is a significant step for Lunit in its mission to advance the cancer care landscape worldwide", said Brandon Suh, CEO of Lunit.. As a leading destination for medical AI companies in Southeast Asia and the largest contributor to the market in the region, this collaboration holds tremendous potential, particularly given Singapore's position as a primary destination for medical AI companies in the region. As a result of this, Singapore will not only be able to gain significant advantages, but we will also be able to gain access to the broader Southeast Asian market as well
As a result of this, Singapore will not only be able to gain significant advantages, but we will also be able to gain access to the broader Southeast Asian market as well
A little bit about Lunit
We are a deep learning-based medical AI company, founded in 2013, dedicated to finding a cure for cancer by harnessing AI to make sure accurate diagnosis and optimal treatment is delivered to all cancer patients using AI-powered medical image analytics and AI biomarkers.
We are a medical AI company founded on clinical evidence, and our findings have been published in major peer-reviewed journals, such as the Journal of Clinical Oncology and the Lancet Digital Health, as well as major conferences, such as ASCO and RSNA. 
We have received FDA clearance as well as the CE Mark for our flagship Lunit INSIGHT suite, which has been clinically used by over 3,000 hospitals and medical institutions in over 40 countries since it was launched. In addition to its headquarters in Seoul, South Korea, Lunit also has offices and representatives throughout the world. To learn more, please visit lunit.io.
The source is Lunit
It has been announced that Lunit Corporation (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, has published a study in the scientific journal npj Precision Medicine...
In a recent study recently published in the journal Cancer Discovery, Lunit (KRX:328130.KQ), a company specializing in AI-based solutions for cancer diagnostics and therapeutics, reported impressive results.
Get PRN's top stories and curated news delivered straight to your inbox every week by signing up here.

Source prnewswire